The PCDx test provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and comprehensive inventory of relevant clinical trials.Continue reading
Changes in the DNA sequence of chromosomes, including insertions, deletions and base substitutions. Somatic mutation analysis has become standard of practice for solid tumors in order to identify therapeutic sensitizing and resistance mutations (e.g., EGFR, KRAS, BRAF).
CNVs are alterations of the DNA of the cancer genome that result in the cell having abnormal copies of one or more sections of the DNA. These alterations can have a significant impact on response to therapy (e.g., HER2).
Gene expression is the process by which information from a gene is used in the synthesis of a functional protein. Sequencing-based mRNA analysis enables the significant multiplexing of biomarker targets (e.g., ER, ERCC1).
Changes in the protein expression as measured by IHC has been utilized for many years as the gold-standard to quantitate the actual translation of altered gene products. Our ability to interrogate key protein markers (e.g. PD-L1, HER2, AR, MGMT, TOP1) provides insights on potential response to both cytotoxic agents as well as emerging clinical trials.
Paradigm promises a clinically relevant turnaround time. Customers can expect 4 to 5 days from sample receipt to reporting ensures continuity of clinical care.
Paradigm 5000x average depth of coverage ensures confidence in that both positive and negative calls are correct. This level of assurance is unique to Paradigm.
mRNA targets account for a significant number of PCDx’s actionable results and is not commercially available with associated DNA findings outside of Paradigm.
PCDx assesses the most clinically-actionable genomic variations in cancer, including: mutations, copy number variations, mRNA expression and protein expression.